Asia Pacific Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity

Asia Pacific preventive vaccines market will grow by 12.89% annually with a total addressable market cap of $97.2 billion over 2020-2026 owing to the rising healthcare expenditure, advancing vaccine technology, and rising need for preventive vaccines especially new COVID-19 vaccines.
Highlighted with 33 tables and 51 figures, this 119-page report “Asia Pacific Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity” is based on a holistic research of the entire Asia Pacific preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2016-2019 and provides forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.

Based on Vaccine Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• Recombinant Vector Vaccines
• Other Vaccines

Based on Disease, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Vaccines for Pneumococcal Disease
• Vaccines for Poliovirus
• Vaccines for Hepatitis
• Vaccines for Influenza
• Vaccines for Measles, Mumps, and Rubella (MMR)
• Vaccines for Varicella
• Vaccines for Human Papilloma Virus
• Vaccines for COVID-19
• Vaccines for Other Diseases

Based on Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes

Based on Patient, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
Pediatric Vaccines
• Pneumococcal
• Measles, Mumps, and Rubella (MMR)
• Varicella
• Hepatitis
• Poliovirus
• Haemophilus Influenzae B (HIB)
• Other Diseases
Adult Vaccines
• Influenza
• Cervical Cancer
• Hepatitis
• Zoster
• Other Diseases

Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2016-2026. The breakdown of key national markets by Vaccine Type, Disease, and Route of Administration over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific preventive vaccines market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline PLC
Johnson & Johnson
Merck & Co.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 25
2.2 Major Growth Drivers 27
2.3 Market Restraints and Challenges 30
2.4 Emerging Opportunities and Market Trends 33
2.5 Porter’s Fiver Forces Analysis 37
3 Segmentation of Asia Pacific Market by Vaccine Type 41
3.1 Market Overview by Vaccine Type 41
3.2 Live/Attenuated Vaccines 43
3.3 Inactivated Vaccines 44
3.4 Subunit Vaccines 45
3.5 Toxoid Vaccines 46
3.6 Conjugate Vaccines 47
3.7 Recombinant Vector Vaccines 48
3.8 Other Vaccines 49
4 Segmentation of Asia Pacific Market by Disease 50
4.1 Market Overview by Disease 50
4.2 Vaccines for Pneumococcal Disease 52
4.3 Vaccines for Poliovirus 53
4.4 Vaccines for Hepatitis 54
4.5 Vaccines for Influenza 55
4.6 Vaccines for Measles, Mumps, and Rubella (MMR) 56
4.7 Vaccines for Varicella 57
4.8 Vaccines for Human Papilloma Virus 58
4.9 Vaccines for COVID-19 59
4.10 Vaccines for Other Diseases 60
5 Segmentation of Asia Pacific Market by Administration 61
5.1 Market Overview by Administration 61
5.2 Intramuscular Route 63
5.3 Subcutaneous Route 64
5.4 Oral Route 65
5.5 Intravenous Injection 66
5.6 Other Administration Routes 67
6 Segmentation of Asia Pacific Market by Patient 68
6.1 Market Overview by Patient 68
6.2 Pediatric Vaccines 70
6.3 Adult Vaccines 72
7 Asia-Pacific Market 2019-2026 by Country 74
7.1 Overview of Asia-Pacific Market 74
7.2 China 77
7.3 Japan 80
7.4 India 84
7.5 Australia 87
7.6 South Korea 90
7.7 Rest of APAC Region 93
8 Competitive Landscape 95
8.1 Overview of Key Vendors 95
8.2 New Product Launch, Partnership, Investment, and M&A 98
8.3 Company Profiles 99
AstraZeneca plc 99
Bavarian Nordic A/S 101
China National Biotec Group Company Ltd. 102
CSL Ltd. 103
Daiichi Sankyo Co. Ltd 104
Emergent BioSolutions Inc. 105
GlaxoSmithKline PLC 106
Johnson & Johnson 107
Merck & Co. 108
Novavax, Inc. 109
Pfizer Inc. 110
Sanofi SA 111
Takeda Pharmaceutical Co. Ltd 112
9 Investing in Asia Pacific Market: Risk Assessment and Management 113
9.1 Risk Evaluation of Asia Pacific Market 113
9.2 Critical Success Factors (CSFs) 116
Related Reports and Products 119

Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline PLC
Johnson & Johnson
Merck & Co.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd
Table 1. Snapshot of Asia Pacific Preventive Vaccines Market in Balanced Perspective, 2019-2026 18
Table 2. Growth Rate of World Real GDP, 2017-2021 23
Table 3. Main Product Trends and Market Opportunities in Asia Pacific Preventive Vaccines Market 33
Table 4. Asia Pacific Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 41
Table 5. Asia Pacific Preventive Vaccines Market by Disease, 2016-2026, $ mn 50
Table 6. Asia Pacific Preventive Vaccines Market by Administration, 2016-2026, $ mn 61
Table 7. Asia Pacific Preventive Vaccines Market by Patient, 2016-2026, $ mn 68
Table 8. Asia Pacific Preventive Vaccines Market: Pediatric Vaccines by Disease, 2016-2026, $ mn 71
Table 9. Asia Pacific Preventive Vaccines Market: Adult Vaccines by Disease, 2016-2026, $ mn 73
Table 10. APAC Preventive Vaccines Market by Country, 2016-2026, $ mn 75
Table 11. China Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 78
Table 12. China Preventive Vaccines Market by Disease, 2016-2026, $ mn 78
Table 13. China Preventive Vaccines Market by Administration, 2016-2026, $ mn 79
Table 14. Japan Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 82
Table 15. Japan Preventive Vaccines Market by Disease, 2016-2026, $ mn 82
Table 16. Japan Preventive Vaccines Market by Administration, 2016-2026, $ mn 83
Table 17. India Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 85
Table 18. India Preventive Vaccines Market by Disease, 2016-2026, $ mn 85
Table 19. India Preventive Vaccines Market by C Administration, 2016-2026, $ mn 86
Table 20. Australia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 88
Table 21. Australia Preventive Vaccines Market by Disease, 2016-2026, $ mn 88
Table 22. Australia Preventive Vaccines Market by Administration, 2016-2026, $ mn 89
Table 23. South Korea Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 91
Table 24. South Korea Preventive Vaccines Market by Disease, 2016-2026, $ mn 91
Table 25. South Korea Preventive Vaccines Market by Administration, 2016-2026, $ mn 92
Table 26. Preventive Vaccines Market in Rest of APAC by Country, 2016-2026, $ mn 94
Table 27. AstraZeneca plc: Company Snapshot 99
Table 28. AstraZeneca plc: Business Segmentation 99
Table 29. AstraZeneca plc: Product Portfolio 100
Table 30. AstraZeneca plc: Revenue, 2016-2018, $ mn 100
Table 31. AstraZeneca plc: Recent Developments 100
Table 32. Risk Evaluation for Investing in Asia Pacific Market, 2019-2026 114
Table 33. Critical Success Factors and Key Takeaways 117
Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026 17
Figure 5. Asia Pacific Preventive Vaccines Market, 2019-2026, $ mn 20
Figure 6. Development Stages of Preventive Vaccines 21
Figure 7. Impact of COVID-19 on Business 25
Figure 8. Primary Drivers and Impact Factors of Asia Pacific Preventive Vaccines Market 27
Figure 9. Primary Restraints and Impact Factors of Asia Pacific Preventive Vaccines Market 30
Figure 10. Investment Opportunity Analysis 34
Figure 11. Porter’s Fiver Forces Analysis of Asia Pacific Preventive Vaccines Market 37
Figure 12. Breakdown of Asia Pacific Preventive Vaccines Market by Vaccine Type, 2019-2026, % of Revenue 42
Figure 13. Contribution to Asia Pacific 2020-2026 Cumulative Revenue by Vaccine Type, Value ($ mn) and Share (%) 42
Figure 14. Asia Pacific Preventive Vaccines Market: Live/Attenuated Vaccines, 2016-2026, $ mn 43
Figure 15. Asia Pacific Preventive Vaccines Market: Inactivated Vaccines, 2016-2026, $ mn 44
Figure 16. Asia Pacific Preventive Vaccines Market: Subunit Vaccines, 2016-2026, $ mn 45
Figure 17. Asia Pacific Preventive Vaccines Market: Toxoid Vaccines, 2016-2026, $ mn 46
Figure 18. Asia Pacific Preventive Vaccines Market: Conjugate Vaccines, 2016-2026, $ mn 47
Figure 19. Asia Pacific Preventive Vaccines Market: Recombinant Vector Vaccines, 2016-2026, $ mn 48
Figure 20. Asia Pacific Preventive Vaccines Market: Other Vaccines, 2016-2026, $ mn 49
Figure 21. Breakdown of Asia Pacific Preventive Vaccines Market by Disease, 2019-2026, % of Revenue 51
Figure 22. Contribution to Asia Pacific 2020-2026 Cumulative Revenue by Disease, Value ($ mn) and Share (%) 51
Figure 23. Asia Pacific Preventive Vaccines Market: Vaccines for Pneumococcal Disease, 2016-2026, $ mn 52
Figure 24. Asia Pacific Preventive Vaccines Market: Vaccines for Poliovirus, 2016-2026, $ mn 53
Figure 25. Asia Pacific Preventive Vaccines Market: Vaccines for Hepatitis, 2016-2026, $ mn 54
Figure 26. Asia Pacific Preventive Vaccines Market: Vaccines for Influenza, 2016-2026, $ mn 55
Figure 27. Asia Pacific Preventive Vaccines Market: Vaccines for Measles, Mumps, and Rubella (MMR), 2016-2026, $ mn 56
Figure 28. Asia Pacific Preventive Vaccines Market: Vaccines for Varicella, 2016-2026, $ mn 57
Figure 29. Asia Pacific Preventive Vaccines Market: Vaccines for Human Papilloma Virus, 2016-2026, $ mn 58
Figure 30. Asia Pacific Preventive Vaccines Market: Vaccines for COVID-19, 2016-2026, $ mn 59
Figure 31. Asia Pacific Preventive Vaccines Market: Vaccines for Other Diseases, 2016-2026, $ mn 60
Figure 32. Breakdown of Asia Pacific Preventive Vaccines Market by Administration, 2019-2026, % of Revenue 62
Figure 33. Contribution to Asia Pacific 2020-2026 Cumulative Revenue by Administration, Value ($ mn) and Share (%) 62
Figure 34. Asia Pacific Preventive Vaccines Market: Intramuscular Route, 2016-2026, $ mn 63
Figure 35. Asia Pacific Preventive Vaccines Market: Subcutaneous Route, 2016-2026, $ mn 64
Figure 36. Asia Pacific Preventive Vaccines Market: Oral Route, 2016-2026, $ mn 65
Figure 37. Asia Pacific Preventive Vaccines Market: Intravenous Injection, 2016-2026, $ mn 66
Figure 38. Asia Pacific Preventive Vaccines Market: Other Administration Routes, 2016-2026, $ mn 67
Figure 39. Breakdown of Asia Pacific Preventive Vaccines Market by Patient, 2019-2026, % of Revenue 68
Figure 40. Contribution to Asia Pacific 2020-2026 Cumulative Revenue by Patient, Value ($ mn) and Share (%) 69
Figure 41. Asia Pacific Preventive Vaccines Market: Pediatric Vaccines, 2016-2026, $ mn 70
Figure 42. Asia Pacific Preventive Vaccines Market: Adult Vaccines, 2016-2026, $ mn 72
Figure 43. Breakdown of APAC Preventive Vaccines Market by Country, 2019 and 2026, % of Revenue 75
Figure 44. Contribution to APAC 2020-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 76
Figure 45. Preventive Vaccines Market in China, 2016-2026, $ mn 77
Figure 46. Preventive Vaccines Market in Japan, 2016-2026, $ mn 81
Figure 47. Preventive Vaccines Market in India, 2016-2026, $ mn 84
Figure 48. Preventive Vaccines Market in Australia, 2016-2026, $ mn 87
Figure 49. Preventive Vaccines Market in South Korea, 2016-2026, $ mn 90
Figure 50. Preventive Vaccines Market in Rest of APAC, 2016-2026, $ mn 93
Figure 51. Growth Stage of Asia Pacific Preventive Vaccines Industry over the Forecast Period 95

Frequently Asked Questions About This Report

Choose License Type

Each market study on Reports Globe will be revised based on COVID-19 impact analysis

How can we help you?

Our salient features

Best Solution

We will help you understand value propositions of various reports across numerous domains and suggest the best possible solution to suffice your research needs.

Customized Research

Our team of analysts and consultants provide assistance for customized research requirements

Max ROI

Guaranteed maximum assistance to help you get your reports at the optimum prices, thereby ensuring maximum returns on investment.

24/7 Support

24X7 availability to help you through the buying process as well as answer any of your doubts.

Our Clients

We've Received Your Request

We Thank You for filling out your requirements. Our sales team will get in touch with you shortly.